<qa>  What is the status of the patient?Patients who fail therapy with imatinib mesylate and are eligible for an allogeneic transplantation are stratified according to availability of donor HLA-identical related vs unrelated, status, and participating center. Patients are randomized to receive an allogeneic transplantation or continue any salvage therapy. 